en · de · es · fr · pt
field-notes.peptides3626.com › Info › Analytical Detection And Stability — What the Evidence Shows

Analytical Detection And Stability — What the Evidence Shows

By Editorial Desk · published 2025-08-26 · last reviewed 2025-10-08 · Info

The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Sr9009 at a glance

PropertyValueNotes
Common synonymsSR9009; StenabolicNickname is not a chemical name.
Typical analytical methodLC-MS/MSOften with isotope-labeled internal standard.
Storage temperature-20 °CDesiccated and protected from light.
Solution stabilityDMSO stock; avoid freeze-thawStore at -20 to -80 °C.
Regulatory statusNot approved; varies by countryMay be restricted as research chemical.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Related pages on this site

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Further detail

=== Animal health === One meta-analysis published in 2003 suggested a negative impact of rBST's effects on bovine health. Findings suggested an average increase in milk output ranging from 11–16%, an approximate 24% increase in the risk of clinical mastitis, a 40% reduction in fertility, and 55% increased risk of developing clinical signs of lameness. The same study reported a decrease in body condition score for cows treated with rBST, though an increase in their dry matter intake occurred. Another meta-analysis (2003) reported on body condition scores (BCS) but could not reach a conclusion due to lack of homogeneity in study design and reporting. They found a trend towards decreased BCS in treated cows but state "Depending on the level of body condition in these cows, this effect may have been beneficial or detrimental." This analysis did not report on clinical mastitis. A more recent meta-analysis (2014) published by the Journal of the American Veterinary Medical Association showed no significant increase in risk of clinical mastitis nor other adverse effects on cow health and well-being. This review included 26 peer-reviewed studies that involved the use of the rBST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days after birth), dose (500 mg, every 14 days), and route (subcutaneous). Mastitis has cost American dairy industries an estimated $1.5 to 2 billion per year in treating dairy cows.

=== Series of coups d'état === On 10 February 1988, Rocky Malebane-Metsing of the People's Progressive Party (PPP) became the president of Bophuthatswana for one day when he took over the government through a military coup. He accused Mangope of corruption and charged that the recent election had been rigged in the government's favour. A statement by the defence force said "serious and disturbing matters of great concern" had emerged, citing Mangope's close association with a multimillionaire Israeli Soviet émigré Shabtai Kalmanovich. Subsequently, the South African Defence Force invaded Bophuthatswana and Mangope was reinstated and continued his term unabated. P. W. Botha, State President of South Africa at the time, justified the reinstatement by saying that "[t]he South African Government is opposed in principle to the obtaining or maintaining of power by violence." In 1990, a second coup attempt took place in which an estimated 50,000 protesters demanded the President's resignation over his handling of the economy. The New York Times reported that seven people had been killed and 450 wounded "after police officers in armoured cars fired their rifles into the crowds and used tear gas and rubber bullets". After Mangope had asked for help from the South African government, he declared a state of emergency and cut telephone links to the territory "for political reasons", claiming that "normal laws had become inadequate". Human Rights Watch put the number of protesters at 150,000.

In 1969, Williams made a special effort to instruct Epstein on how to improve as a hitter, with a focus on teaching Epstein to only swing at strikes. That year, Epstein had career highs in batting average, home runs, bases on balls, runs batted in, runs scored, on-base percentage, and slugging percentage. In only 18 more at-bats in 1969 than 1968, he had 17 more home runs, 33 more runs and 52 more RBIs; and his batting average increased from .234 to .278. In 1970, however, Epstein's hitting declined as his average against left-handed pitching fell considerably. In May 1971, he was traded along with Darold Knowles to the Oakland Athletics for Frank Fernandez, Don Mincher, Paul Lindblad, and cash. In 1971, while hitting 18 home runs in 329 at bats, he was hit by a pitch 12 times, leading the league. In 1972 he hit 26 home runs (3rd in the league) for the world champion Athletics. He hit a home run every 17.5 at bats (3rd in the AL), had a .490 slugging percentage (5th), had a .376 on-base percentage (6th), collected 62 walks (10th), and was hit by a pitch 11 times (2nd). He was 16th in voting for the American League MVP. However, in late May, while on the road in Arlington Texas, Epstein and slugger Reggie Jackson came to blows in the clubhouse over Epstein's use of complimentary tickets for family members. The next day, owner Charlie Finley asked him about the incident. Finley claimed Epstein attacked his star player (Jackson). Epstein disputed that, claimed that Jackson was the problem, and demanded to be traded.

Some people, however, can continue to lose potassium while on an ACE inhibitor. Hyperkalemia may decrease the velocity of impulse conduction in the nerves and muscles, including cardiac tissues. This leads to cardiac dysfunction and neuromuscular consequences, such as muscle weakness, paresthesia, nausea, diarrhea, and others. Close monitoring of potassium levels is required in patients receiving treatment with ACE inhibitors who are at risk of hyperkalemia. Another possible adverse effect specific for ACE inhibitors, but not for other RAAS blockers, is an increase in bradykinin level. Additional research on this topic is required. A persistent dry cough is a common adverse effect produced by ACE inhibitors in 10% to 20% of patients. People who experience coughing are often switched to angiotensin II receptor antagonists. Between 0.1% and 0.7% of patients develop angioedema or swelling. A genetic predisposition may exist.

Sources: en.wikipedia.org

Background from the literature

==== Synteny-based approaches ==== Synteny-based approaches use order and relative positioning of genes (or other features) to identify the potential ancestors of candidate de novo genes. Syntenic alignments are anchored by conserved "markers." Genes are the most common marker in defining syntenic blocks, although k-mers and exons are also used. Confirmation that the syntenic region lacks coding potential in outgroup species allows a de novo origin to be asserted with higher confidence. The strongest possible evidence for de novo emergence is the inference of the specific "enabling" mutation(s) that created coding potential, typically through the analysis of smaller sequence regions, termed microsyntenic regions, of closely related species. One challenge in applying synteny-based methods is that synteny can be difficult to detect across longer timescales. To address this, various optimization techniques have been created, such as using exons clustered irrespective of their specific order to define syntenic blocks or algorithms that use well-conserved genomic regions to expand microsyntenic blocks. There are also difficulties associated with applying synteny-based approaches to genome assemblies that are fragmented or in lineages with high rates of chromosomal rearrangements, as is common in insects. Synteny-based approaches can be applied to genome-wide surveys of de novo genes and represent a promising area of algorithmic development for gene birth dating.

1991: Invercargill re-proclaimed a city. 1992: Nelson-Marlborough Regional Council abolished by a Local Government Amendment Act. Of its territorial authorities, the Kaikōura District was transferred to the Canterbury Region, and Nelson City and Tasman and Marlborough districts became unitary authorities. 1995: The Chatham Islands County was dissolved and reconstituted by an Act of Parliament as the "Chatham Islands Territory", with powers similar to those of territorial authorities and some functions similar to those of a regional council. 2004: Tauranga became a city again on 1 March. 2006: The Banks Peninsula District merged into Christchurch as a result of a 2005 referendum. 2010: Auckland Council, a unitary authority, replaced seven local councils and the regional council. Reports on completed reorganisation proposals since 1999 are available on the Local Government Commission's site (link below).

== History == Dehydrated meat stock, in the form of tablets, was known in the 17th century to English food writer Anne Blencowe, who died in 1718, and elsewhere as early as 1735. Various French cooks in the early 19th century (Lefesse, Massué, and Martin) tried to patent bouillon cubes and tablets, but were turned down for lack of originality. Nicolas Appert also proposed such dehydrated bouillon in 1831. Portable soup was a kind of dehydrated food used in the 18th and 19th centuries. It was a precursor of meat extract and bouillon cubes, and of industrially dehydrated food. It is also known as pocket soup or veal glue. It is a cousin of the glace de viande of French cooking. It was long a staple of seamen and explorers, for it would keep for many months or even years. In this context, it was a filling and nutritious dish. Portable soup of less extended vintage was, according to the 1881 Household Cyclopedia, "exceedingly convenient for private families, for by putting one of the cakes in a saucepan with about a quart of water, and a little salt, a basin of good broth may be made in a few minutes." In the mid-19th century, German chemist Justus von Liebig developed meat extract, but it was more expensive than bouillon cubes. It is essentially only dehydrated meat stock. Industrially produced bouillon cubes were commercialized by Maggi in 1908, by Oxo in 1910, and by Knorr in 1912. By 1913, at least 10 brands were available, with salt contents of 59–72%.

=== 241Am === Americium-241 is a candidate isotope with much greater availability than 238Pu. Though 241Am has a half-life of 432 years, which is about five times longer than that of 238Pu and could hypothetically power a device for centuries, missions with more than 10 years were not the subject of the research until 2019. The power density of 241Am is only one-fourth that of 238Pu, and 241Am produces more penetrating radiation through decay chain products than 238Pu and needs more shielding. Its shielding requirements in a RTG are the third lowest: only 238Pu and 210Po require less. With a current global shortage of 238Pu, 241Am is being studied as RTG fuel by ESA and in 2019, UK's National Nuclear Laboratory announced the generation of usable electricity. An advantage over 238Pu is that it is produced as nuclear waste and is nearly isotopically pure. Prototype designs of 241Am RTGs expect 2–2.2 We/kg for 5–50 We RTGs design but in practical testing dropped to 1.3–1.9 We/kg. Americium-241 is currently used in small quantities in household smoke detectors and thus its handling and properties are well-established. However, it decays to neptunium-237, the most chemically mobile among the actinides.

== Organizations == SST Inc. also known as ShotSpotter Inc. Silicon Storage Technology, Inc, former US semiconductor manufacturer School of Science and Technology, high school in Oregon, US School of Science and Technology, Singapore Special Security Team, a counter-terrorist unit of the Japanese Coast Guard

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

What storage conditions are typical for SR9009?

Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.

Network